Linscomb Wealth Inc. Increases Stock Position in Veeva Systems Inc. $VEEV

Linscomb Wealth Inc. raised its stake in shares of Veeva Systems Inc. (NYSE:VEEV) by 4.8% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 12,619 shares of the technology company’s stock after purchasing an additional 573 shares during the quarter. Linscomb Wealth Inc.’s holdings in Veeva Systems were worth $3,634,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Keybank National Association OH boosted its stake in Veeva Systems by 1.4% during the 2nd quarter. Keybank National Association OH now owns 3,088 shares of the technology company’s stock valued at $889,000 after acquiring an additional 42 shares during the last quarter. Facet Wealth Inc. raised its position in shares of Veeva Systems by 3.3% during the 2nd quarter. Facet Wealth Inc. now owns 1,342 shares of the technology company’s stock worth $381,000 after buying an additional 43 shares in the last quarter. TFB Advisors LLC grew its stake in shares of Veeva Systems by 1.2% in the 1st quarter. TFB Advisors LLC now owns 3,586 shares of the technology company’s stock worth $831,000 after purchasing an additional 44 shares during the last quarter. Triangle Securities Wealth Management grew its stake in shares of Veeva Systems by 0.8% in the 2nd quarter. Triangle Securities Wealth Management now owns 5,782 shares of the technology company’s stock worth $1,665,000 after purchasing an additional 45 shares during the last quarter. Finally, Marks Group Wealth Management Inc boosted its holdings in shares of Veeva Systems by 3.3% in the first quarter. Marks Group Wealth Management Inc now owns 1,427 shares of the technology company’s stock worth $331,000 after buying an additional 46 shares during the period. 88.20% of the stock is currently owned by hedge funds and other institutional investors.

Veeva Systems Price Performance

Veeva Systems stock opened at $291.20 on Friday. The firm has a market cap of $47.73 billion, a P/E ratio of 59.80, a P/E/G ratio of 2.22 and a beta of 0.98. The stock’s 50 day moving average is $285.22 and its 200 day moving average is $272.19. Veeva Systems Inc. has a one year low of $201.54 and a one year high of $310.50.

Veeva Systems (NYSE:VEEV) last announced its quarterly earnings results on Wednesday, August 27th. The technology company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.90 by ($0.64). Veeva Systems had a return on equity of 13.72% and a net margin of 27.29%.The company had revenue of $789.08 million for the quarter, compared to the consensus estimate of $768.49 million. During the same quarter last year, the company posted $1.62 EPS. The company’s quarterly revenue was up 16.7% compared to the same quarter last year. Veeva Systems has set its Q3 2026 guidance at 1.940-1.950 EPS. FY 2026 guidance at 7.780-7.780 EPS. Equities analysts anticipate that Veeva Systems Inc. will post 4.35 earnings per share for the current fiscal year.

Insider Activity at Veeva Systems

In other news, insider Eleni Nitsa Zuppas sold 6,000 shares of Veeva Systems stock in a transaction that occurred on Tuesday, October 7th. The stock was sold at an average price of $306.62, for a total value of $1,839,720.00. Following the sale, the insider directly owned 25,325 shares in the company, valued at approximately $7,765,151.50. This trade represents a 19.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Thomas D. Schwenger sold 3,350 shares of the firm’s stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $300.04, for a total value of $1,005,134.00. Following the completion of the transaction, the insider owned 23,773 shares of the company’s stock, valued at approximately $7,132,850.92. The trade was a 12.35% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 24,665 shares of company stock worth $7,438,000 in the last ninety days. 10.30% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on VEEV shares. Weiss Ratings reiterated a “hold (c+)” rating on shares of Veeva Systems in a research note on Wednesday, October 8th. UBS Group boosted their target price on shares of Veeva Systems from $285.00 to $310.00 and gave the company a “neutral” rating in a research note on Thursday, August 28th. Barclays upped their price target on shares of Veeva Systems from $300.00 to $325.00 and gave the stock an “overweight” rating in a research report on Thursday, August 28th. Piper Sandler upped their price target on Veeva Systems from $325.00 to $355.00 and gave the company an “overweight” rating in a research note on Thursday, August 28th. Finally, KeyCorp increased their target price on Veeva Systems from $285.00 to $325.00 and gave the stock an “overweight” rating in a research note on Monday, July 14th. Seventeen equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Veeva Systems currently has a consensus rating of “Moderate Buy” and a consensus target price of $307.58.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.